市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Savara, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 3.0 |
| 内部交易活动 | -4.0 |
| 价格波动 | -3.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 4.0 |
| 平均 | 0.50 |
|
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 5.38% |
| 机构持股比例 | 98.53% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 11.00 (JMP Securities, 58.50%) | 购买 |
| 中 | 9.50 (36.89%) | |
| 低 | 9.00 (Wells Fargo, 29.68%) | 购买 |
| 9.00 (Oppenheimer, 29.68%) | 购买 | |
| 平均值 | 9.75 (40.49%) | |
| 总计 | 4 购买 | |
| 平均价格@调整类型 | 4.82 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Wells Fargo | 18 Dec 2025 | 9.00 (29.68%) | 购买 | 6.59 |
| Oppenheimer | 14 Nov 2025 | 9.00 (29.68%) | 购买 | 4.30 |
| Citizens | 13 Nov 2025 | 10.00 (44.09%) | 购买 | 4.26 |
| JMP Securities | 23 Oct 2025 | 11.00 (58.50%) | 购买 | 4.12 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合